ADMA Biologics: Funding, Investors & Team (Oct 2026)
ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. ADMA also operates ADMA BioCenters, FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacturing of the Company’s lead product candidate RI-002.
ADMA Biologics has raised $645M across 4 funding rounds on record, the most recent an undisclosed round of $300M announced in Aug 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ADMA Biologics Company Profile and Key Stats
Latest funding round on record: Aug 2025.
ADMA Biologics Funding Rounds
ADMA Biologics raised $150M in a Post-IPO Debt announced in Mar 2022.
9 months later, an undisclosed round of $60.0M was announced in Dec 2022.
1 years later, an undisclosed round of $135M was announced in Dec 2023.
1.7 years later, an undisclosed round of $300M was announced in Aug 2025.
ADMA Biologics Founders and Leadership Team
No contact details are on record for this team yet.
ADMA Biologics Funding Compared to Other Biotechnology Startups
ADMA Biologics' latest round of $300M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ADMA Biologics in Biotechnology and Ramsey
Companies Similar to ADMA Biologics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
ADMA Biologics Funding FAQs
What does ADMA Biologics do?
ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. ADMA also operates ADMA BioCenters, FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacturing of the Company’s lead product candidate RI-002.
How much funding has ADMA Biologics raised?
ADMA Biologics has raised $645M across 4 rounds on record. The most recent is an undisclosed round of $300M announced in Aug 2025.
When did ADMA Biologics last raise funding?
ADMA Biologics' most recent funding round on record is an undisclosed round of $300M, announced in Aug 2025.
Who founded ADMA Biologics?
FundedIQ lists Jerrold B Grossman (Founder) at ADMA Biologics.
Who is the CEO of ADMA Biologics?
Adam Grossman is listed as CEO at ADMA Biologics.
Where is ADMA Biologics headquartered?
ADMA Biologics is based in Ramsey, New Jersey, United States.
How many employees does ADMA Biologics have?
ADMA Biologics is in the 251-500 employee band.
How does ADMA Biologics' funding compare to other Biotechnology startups?
ADMA Biologics' latest round of $300M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's ADMA Biologics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ADMA Biologics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.